Desensitization Therapy for Allergy: Chronic Immunotherapy vs Acute Drug Desensitization

Allergy desensitization therapy is the historical term for what is now called subcutaneous immunotherapy (SCIT) — the 3-to-5-year course of escalating subcutaneous allergen extract injections defined by Cox L et al (JACI 2011;127[1 Suppl]:S1-S55). The treatment induces allergen-specific tolerance through regulatory T cells, blocking IgG4 antibodies, and progressive reduction of mast-cell and eosinophil activity in target tissues. The term originated with Noon L (Lancet 1911;1:1572-1573), whose concept of 'desensitization' via gradually increasing pollen doses remains mechanistically accurate. US practice shifted to 'immunotherapy' around 2010 to reduce confusion with acute drug-desensitization protocols.

Aeroallergen desensitization (SCIT) is a 3-to-5-year course that induces durable allergen-specific tolerance through regulatory T cells and blocking IgG4 antibodies — benefits persist for years after stopping. Acute drug desensitization is a completely different inpatient or monitored procedure lasting hours to days, used to allow a patient to receive a critical medication (such as penicillin, platinum chemotherapy, or aspirin) to which they have hypersensitivity. Drug desensitization achieves temporary mast-cell tolerance for the duration of that drug course; the patient returns to full sensitivity once the drug clears and must undergo the protocol again if the drug is needed in the future.

Yes. The evidence base is among the strongest in clinical allergology. Calderón MA et al (Cochrane Database Syst Rev 2007, 51 RCTs, 2,871 patients) found a pooled symptom-score SMD of -0.73 and medication-score SMD of -0.57 in favor of SCIT versus placebo for seasonal allergic rhinitis. Durham SR et al (NEJM 1999;341:468-475) showed that a 3-year grass-pollen desensitization course produced 4 additional years of symptom-free outcomes after stopping. Jacobsen L et al (Allergy 2007) found that pediatric pollen desensitization cut subsequent asthma development by approximately half at 10-year follow-up — the only intervention with this asthma-prevention evidence.

Aeroallergen desensitization therapy (SCIT) requires 3-5 years per Cox 2011 PP3. The build-up phase involves approximately 26-28 weekly injections over 4-6 months (~39 total Year-1 clinic visits including early maintenance under the traditional in-clinic model). The maintenance phase continues every 2-4 weeks for the remaining years. A 30-minute post-injection observation period applies to every clinic visit; for eligible maintenance patients, Curex now delivers the same weekly injection at home for $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Shorter courses (2 years) are associated with higher relapse rates per Scadding GK et al (JAMA 2017). Most patients notice meaningful improvement within the first year of reaching maintenance.

Yes. Sublingual immunotherapy (SLIT) uses the same allergen extracts as SCIT but delivers them under the tongue rather than by injection. SLIT drops (compounded liquid, off-label in the US) and FDA-approved SLIT tablets (Grastek for Timothy grass, Oralair for 5-grass mix, Ragwitek for short ragweed, Odactra for house dust mite) are the needle-free alternatives. Both achieve allergen desensitization through the same Treg-induction and blocking-IgG4 mechanism as SCIT, with no injections and no 30-minute in-clinic observation required. SLIT tablets require a supervised first dose due to a boxed anaphylaxis warning but subsequent doses are taken at home.